<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738773</url>
  </required_header>
  <id_info>
    <org_study_id>Gambling Natrexone ET</org_study_id>
    <nct_id>NCT04738773</nct_id>
  </id_info>
  <brief_title>RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response</brief_title>
  <official_title>Double Blind 12-week Controlled Experiment With Two Groups of Pathological Gamblers, One Taking Active Drug (Naltrexone) and the Other Receiving Placebo.Patters Patterns of Visual Tracking Will be Acessed on Both Groups Prior and During Tratment in Order to Predict Treatment Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether favorable response to naltrexone&#xD;
      orally taken in treatment of GD can be predicted by patterns of visual scanning, assessed by&#xD;
      eye-tracking technology before, at the start and throughout gambling treatment with&#xD;
      naltrexone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a double blind 12-week controlled trial with two groups, one taking active&#xD;
      drug (naltrexone) and the other receiving placebo. Patients on both groups will be assessed&#xD;
      for GD symptoms and severity, major comorbid psychiatric disorders and related&#xD;
      psychopathology (impulsivity, craving and locus of control), and eye-tracking patterns prior&#xD;
      to and one hour after the administration of the first dose, one week after and at treatment&#xD;
      completion.&#xD;
&#xD;
      On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg&#xD;
      per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per&#xD;
      day or as much as tolerated by the patient.&#xD;
&#xD;
      On the first day of evaluation patients will first be interviewed to check GD diagnosis and&#xD;
      screen other medical conditions that may exclude patients from the trial. The selected&#xD;
      individuals will be randomly assigned to either naltrexone or placebo group; After that they&#xD;
      will answer several questionnaires and have the first eye tracking assessment. Each&#xD;
      individual will receive either placebo or naltrexone and be assessed 1 hour after drug&#xD;
      administration.&#xD;
&#xD;
      After the first week patients will have the third eye tracking assessment, as well as several&#xD;
      questionnaires On the next weeks patients will be constantly monitored for side effects and&#xD;
      gambling symptoms.&#xD;
&#xD;
      On the twelfth week patients will have the fourth and last eye tracking assessment During the&#xD;
      12-week trial both groups will have psychoeducational sessions, on weeks 2,4,6 and 8. During&#xD;
      sessions patients have access to audio-visual material and receive Self-help material, this&#xD;
      intervention is based on Hodgins proposal (Hodgins DC et al, 2005).&#xD;
&#xD;
      Adherence will be verified by counting pills consumed by the patient. In the weeks without&#xD;
      face-to-face medical assessment, patients will be evaluated by telephone interview to monitor&#xD;
      adverse effects of medication. If the evaluator identifies a worrying adverse reaction, the&#xD;
      patient will be advised to anticipate the face-to-face interview.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gambling Follow up scale (GFS)</measure>
    <time_frame>Day 0 and day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gambling Self-Assessment Scale (G-SAS)</measure>
    <time_frame>Day 0 and day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GamblersÂ´ Beliefs Questionnaires (GBQ)</measure>
    <time_frame>Day 0 and day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timeline Follow-Back Method, (TFB)</measure>
    <time_frame>Day 0 and day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barratt Impulsiveness Scale, version 11</measure>
    <time_frame>Day 0 and day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Adjustment Scale self-report version</measure>
    <time_frame>Day 0 and day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>Day 0 and day 84</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Locus of control scale internal- external</measure>
    <time_frame>Day 0,day 7, and day 84</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Eye Tracking</measure>
    <time_frame>Day 0, day 7 and day 84</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Eye Tracking</condition>
  <condition>Gambling Disorder</condition>
  <condition>Naltrexone</condition>
  <arm_group>
    <arm_group_label>Patients receiving Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.</description>
    <arm_group_label>Patients receiving Naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Patients receiving Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The inclusion criteria are:&#xD;
&#xD;
               1. Men and woman aged 21 to 60 years;&#xD;
&#xD;
               2. Female patients should be:&#xD;
&#xD;
                    -  postmenopausal for at least one year, or;&#xD;
&#xD;
                    -  are surgically unable to become pregnant (undergoing bilateral hysterectomy&#xD;
                       or oophorectomy or tubal ligation or otherwise unable to become pregnant),&#xD;
                       or;&#xD;
&#xD;
                    -  be practicing an acceptable method of birth control (defined as hormonal&#xD;
                       contraceptives, spermicide plus barrier, a single vasectomized partner and /&#xD;
                       or intrauterine device);&#xD;
&#xD;
               3. Have read and signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Hypersensitivity to naltrexone or contraindication of naltrexone use; 2. Exposure&#xD;
             to another pharmacological drug in the last 30 days; 3. Pregnancy or lactation; 4.&#xD;
             Kidney dysfunction: Creatine serum &gt; 133 mmol/L in men &gt; 124 mmol/L in women, which&#xD;
             correspond &gt; 1,51 mg/dL e &gt; 1,41 mg/Dl; 5. Liver dysfunction (aspartate transaminase&#xD;
             (AST) and alanine transaminase (ALT) &gt; 2times the upper limit of normal; 6.&#xD;
             Cardiovascular disease, hypertension; 7. Lifetime history of bipolar disorder,&#xD;
             Obsessive compulsive disorder, schizophrenia or any psychotic disorder, or depression&#xD;
             (BDI&gt; 30 points), clinically significant suicidality; 8. Lifetime history of drug&#xD;
             (except nicotine) or alcohol; 9. Hematologic or immunologic dysfunction; 10. Subjects&#xD;
             receiving psychoactive drugs, except sporadic use of benzodiazepines; 11. Simultaneous&#xD;
             participation in other GD-related; 12. Lack of reliable contact information; 13.&#xD;
             Illiteracy of other condition that difficult reading and understanding the study&#xD;
             questionnaires and orientations; 14. Not having a cellphone line;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hermano Tavares</last_name>
    <phone>55-11-26617805</phone>
    <email>hermanoqt@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rache Takahashi</last_name>
    <phone>55 11 99517953</phone>
    <email>chel_est89@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Altamirano LJ, Fields HL, D'Esposito M, Boettiger CA. Interaction between family history of alcoholism and Locus of Control in the opioid regulation of impulsive responding under the influence of alcohol. Alcohol Clin Exp Res. 2011 Nov;35(11):1905-14. doi: 10.1111/j.1530-0277.2011.01535.x. Epub 2011 May 13.</citation>
    <PMID>21569055</PMID>
  </reference>
  <reference>
    <citation>Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999 Nov;156(11):1758-64.</citation>
    <PMID>10553740</PMID>
  </reference>
  <reference>
    <citation>Brevers D, Cleeremans A, Bechara A, Laloyaux C, Kornreich C, Verbanck P, NoÃ«l X. Time course of attentional bias for gambling information in problem gambling. Psychol Addict Behav. 2011 Dec;25(4):675-82. doi: 10.1037/a0024201. Epub 2011 Jun 20.</citation>
    <PMID>21688874</PMID>
  </reference>
  <reference>
    <citation>Field M, Mogg K, Bradley BP. Cognitive bias and drug craving in recreational cannabis users. Drug Alcohol Depend. 2004 Apr 9;74(1):105-11.</citation>
    <PMID>15072814</PMID>
  </reference>
  <reference>
    <citation>Field M, Mogg K, Zetteler J, Bradley BP. Attentional biases for alcohol cues in heavy and light social drinkers: the roles of initial orienting and maintained attention. Psychopharmacology (Berl). 2004 Oct;176(1):88-93. Epub 2004 Apr 8.</citation>
    <PMID>15071718</PMID>
  </reference>
  <reference>
    <citation>Galetti AM, Tavares H. Development and validation of the Gambling Follow-up Scale, Self-Report version: an outcome measure in the treatment of pathological gambling. Braz J Psychiatry. 2017 Jan-Mar;39(1):36-44. doi: 10.1590/1516-4446-2016-1911. Epub 2016 Nov 7.</citation>
    <PMID>27828667</PMID>
  </reference>
  <reference>
    <citation>Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction. 2014 Aug;109(8):1274-84. doi: 10.1111/add.12557. Epub 2014 May 23. Review.</citation>
    <PMID>24661324</PMID>
  </reference>
  <reference>
    <citation>Grant LD, Bowling AC. Gambling Attitudes and Beliefs Predict Attentional Bias in Non-problem Gamblers. J Gambl Stud. 2015 Dec;31(4):1487-503. doi: 10.1007/s10899-014-9468-z.</citation>
    <PMID>24871298</PMID>
  </reference>
  <reference>
    <citation>Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008 May;69(5):783-9.</citation>
    <PMID>18384246</PMID>
  </reference>
  <reference>
    <citation>Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. Addict Biol. 2017 Nov;22(6):1515-1527. doi: 10.1111/adb.12425. Epub 2016 Jul 14.</citation>
    <PMID>27411969</PMID>
  </reference>
  <reference>
    <citation>Hodgins DC. Implications of a brief intervention trial for problem gambling for future outcome research. J Gambl Stud. 2005 Spring;21(1):13-9. Review.</citation>
    <PMID>15789185</PMID>
  </reference>
  <reference>
    <citation>Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001 Sep;16(5):285-9.</citation>
    <PMID>11552772</PMID>
  </reference>
  <reference>
    <citation>Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001 Jun 1;49(11):914-21.</citation>
    <PMID>11377409</PMID>
  </reference>
  <reference>
    <citation>Lahti T, Halme JT, Pankakoski M, Sinclair D, Alho H. Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull. 2010;43(3):35-44.</citation>
    <PMID>21150845</PMID>
  </reference>
  <reference>
    <citation>Lole L, Li E, Russell AM, Greer N, Thorne H, Hing N. Are sports bettors looking at responsible gambling messages? An eye-tracking study on wagering advertisements. J Behav Addict. 2019 Sep 1;8(3):499-507. doi: 10.1556/2006.8.2019.37. Epub 2019 Aug 26.</citation>
    <PMID>31446764</PMID>
  </reference>
  <reference>
    <citation>McGrath DS, Meitner A, Sears CR. The specificity of attentional biases by type of gambling: An eye-tracking study. PLoS One. 2018 Jan 31;13(1):e0190614. doi: 10.1371/journal.pone.0190614. eCollection 2018.</citation>
    <PMID>29385164</PMID>
  </reference>
  <reference>
    <citation>Mitchell JM, Tavares VC, Fields HL, D'Esposito M, Boettiger CA. Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls. Neuropsychopharmacology. 2007 Feb;32(2):439-49. Epub 2006 Oct 18.</citation>
    <PMID>17047667</PMID>
  </reference>
  <reference>
    <citation>Nestler EJ. From neurobiology to treatment: progress against addiction. Nat Neurosci. 2002 Nov;5 Suppl:1076-9. Review.</citation>
    <PMID>12403990</PMID>
  </reference>
  <reference>
    <citation>O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996 Jan-Feb;13(1):35-9. Review.</citation>
    <PMID>8837932</PMID>
  </reference>
  <reference>
    <citation>Robinson TE, Berridge KC. Addiction. Annu Rev Psychol. 2003;54:25-53. Epub 2002 Jun 10. Review.</citation>
    <PMID>12185211</PMID>
  </reference>
  <reference>
    <citation>Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction. 2001 Jan;96(1):103-14. Review.</citation>
    <PMID>11177523</PMID>
  </reference>
  <reference>
    <citation>Ruddock HK, Field M, Jones A, Hardman CA. State and trait influences on attentional bias to food-cues: The role of hunger, expectancy, and self-perceived food addiction. Appetite. 2018 Dec 1;131:139-147. doi: 10.1016/j.appet.2018.08.038. Epub 2018 Aug 29.</citation>
    <PMID>30171914</PMID>
  </reference>
  <reference>
    <citation>Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001 Jan-Feb;36(1):2-10. Review.</citation>
    <PMID>11139409</PMID>
  </reference>
  <reference>
    <citation>Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997 Mar 14;275(5306):1593-9. Review.</citation>
    <PMID>9054347</PMID>
  </reference>
  <reference>
    <citation>Vitaro F, Hartl AC, Brendgen M, Laursen B, Dionne G, Boivin M. Genetic and environmental influences on gambling and substance use in early adolescence. Behav Genet. 2014 Jul;44(4):347-55. doi: 10.1007/s10519-014-9658-6. Epub 2014 May 14.</citation>
    <PMID>24824822</PMID>
  </reference>
  <reference>
    <citation>Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992 Nov;49(11):876-80.</citation>
    <PMID>1345133</PMID>
  </reference>
  <reference>
    <citation>Wickelgren I. Getting the brain's attention. Science. 1997 Oct 3;278(5335):35-7.</citation>
    <PMID>9340756</PMID>
  </reference>
  <reference>
    <citation>Wilcockson TDW, Pothos EM. Measuring inhibitory processes for alcohol-related attentional biases: introducing a novel attentional bias measure. Addict Behav. 2015 May;44:88-93. doi: 10.1016/j.addbeh.2014.12.015. Epub 2014 Dec 27.</citation>
    <PMID>25583563</PMID>
  </reference>
  <reference>
    <citation>Yau YH, Potenza MN. Gambling disorder and other behavioral addictions: recognition and treatment. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):134-46. doi: 10.1097/HRP.0000000000000051. Review.</citation>
    <PMID>25747926</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Hermano Tavares</investigator_full_name>
    <investigator_title>Associate Profssor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gambling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

